Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness of Selective Serotonin Reuptake Inhibitors Combined With Antipsychotic Medication for the Treatment of Psychotic Depression

Next Previous
Trial Profile

Effectiveness of Selective Serotonin Reuptake Inhibitors Combined With Antipsychotic Medication for the Treatment of Psychotic Depression

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sertraline (Primary) ; Olanzapine
  • Indications Major depressive disorder; Psychotic affective disorders
  • Focus Therapeutic Use
  • Acronyms STOP-PD; STOP-PD II

    • Most Recent Events

    • 15 Mar 2023 Results (n=126) assessing the relationships between participant characteristics and insight into delusions during and at the end of the eight weeks of stabilization treatment and also assessed whether impaired insight into delusions during or at the end of stabilization treatment was associated with risk of relapse of remitted psychotic depression during 36 weeks of continuation treatment, published in the Journal of Affective Disorders.
    • 29 Jun 2018 Results (n=71) published in the Acta Psychiatrica Scandinavica
    • 25 Apr 2017 Results of association of baseline suicidality with study outcome (n=258) published in the Journal of Clinical Psychiatry
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top